Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022

Jiahua Liu; Junnan Ma; Jiarong Zhang; Chengming Li; Bowen Yu; Hyok Chol Choe; Kaiyue Ding; Liu Zhang; Lin Zhang

doi:10.3389/fonc.2023.1173863

Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022

Front Oncol. 2023 May 18:13:1173863. doi: 10.3389/fonc.2023.1173863. eCollection 2023.

Authors

Jiahua Liu¹, Junnan Ma¹, Jiarong Zhang¹, Chengming Li¹, Bowen Yu¹, Hyok Chol Choe¹, Kaiyue Ding¹, Liu Zhang¹, Lin Zhang¹

Affiliation

¹ Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, China.

Abstract

Objective: As one of the cancers that seriously threatens women's health, ovarian cancer has a high morbidity and mortality rate. Surgery and chemotherapy are the basic treatment strategies for ovarian cancer, and chemotherapy resistance is a significant factor in affecting the prognosis, survival cycle, and recurrence of ovarian cancer. This article aims to analyze articles about ovarian cancer and drug resistance via bibliometric software, offering new ideas and directions for researchers in this field.

Methods: Both Citespace and Vosviewer are bibliometric software on the Java platform. Articles were collected on ovarian cancer and drug resistance in the Web of Science Core Collection database from 2013 to 2022. The countries, institutions, journals, authors, keywords, and references were analyzed, and the development status of this field was indicated from multiple perspectives.

Results: Studies on ovarian cancer and drug resistance generally showed an increasing trend from 2013 to 2022. The People's Republic of China and Chinese institutions contributed more to this field. Gynecologic Oncology published the most articles, and the journal with the most citations was Cancer Research. Li Li was the author with the most publications, and Siegel RL was the author with the most citations. Through burst detection, it can be found that the research hotspots in this field mainly focused on the in-depth exploration of the drug resistance mechanism of ovarian cancer and the progress of PARP inhibitors and bevacizumab in the treatment of ovarian cancer.

Conclusions: Many studies on the mechanism of drug resistance in ovarian cancer have been discovered; however, the deeper mechanism remains to be explored. Compared with traditional chemotherapy drugs, PARP inhibitors and bevacizumab have shown better efficacy, but PARP inhibitors have initially shown drug resistance. The future direction of this field should be to overcome the resistance of existing drugs and actively develop new ones.

Keywords: Citespace; PARP inhibitors; Vosviewer; bevacizumab; bibliometric; drug resistance; ovarian cancer.

Publication types

Review

Grants and funding

This work was supported by grants from the National Natural Science Foundation of China (No.81873195), the Liaoning Revitalization Talents Program (XLYC1907113), the Natural Science Foundation of Liaoning Province (2023010109-JH2/1013), the Distinguished Young Scholars in Dalian (2022RJ19), and the Dalian Medical University Foundation for Teaching Reform Project of Undergraduate Innovative Talents Training (111906010210).